Bio-Techne (TECH) Projected to Announce Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is anticipated to announce its Q4 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $0.5190 per share and revenue of $314.6270 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. During the same period in the prior year, the business earned $0.56 earnings per share. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Price Performance

Bio-Techne stock opened at $72.09 on Monday. The stock’s 50 day moving average price is $63.04 and its 200 day moving average price is $59.02. Bio-Techne has a 1-year low of $43.19 and a 1-year high of $72.36. The company has a market cap of $11.29 billion, a PE ratio of 104.48, a price-to-earnings-growth ratio of 8.59 and a beta of 1.28. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.49 and a quick ratio of 3.18.

Bio-Techne Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a $0.08 dividend. The ex-dividend date of this dividend was Monday, May 18th. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. Bio-Techne’s dividend payout ratio (DPR) is 46.38%.

Hedge Funds Weigh In On Bio-Techne

Several hedge funds have recently added to or reduced their stakes in TECH. Morgan Stanley lifted its holdings in shares of Bio-Techne by 15.3% in the fourth quarter. Morgan Stanley now owns 8,345,414 shares of the biotechnology company’s stock valued at $490,794,000 after purchasing an additional 1,107,536 shares in the last quarter. State Street Corp grew its position in shares of Bio-Techne by 1.0% in the fourth quarter. State Street Corp now owns 5,812,032 shares of the biotechnology company’s stock valued at $341,806,000 after purchasing an additional 58,639 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Bio-Techne by 12.1% during the 4th quarter. Wellington Management Group LLP now owns 5,734,049 shares of the biotechnology company’s stock worth $337,219,000 after purchasing an additional 618,916 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Bio-Techne by 21.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,075,194 shares of the biotechnology company’s stock worth $239,663,000 after purchasing an additional 725,050 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Bio-Techne by 7.7% during the 3rd quarter. Invesco Ltd. now owns 3,946,028 shares of the biotechnology company’s stock worth $219,518,000 after purchasing an additional 283,303 shares during the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TECH has been the topic of several research analyst reports. Wells Fargo & Company decreased their target price on shares of Bio-Techne from $76.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Leerink Partners set a $73.00 price target on shares of Bio-Techne in a report on Thursday, June 25th. Stifel Nicolaus set a $50.00 price objective on shares of Bio-Techne in a research note on Thursday, May 7th. Royal Bank Of Canada downgraded shares of Bio-Techne from an “outperform” rating to a “sector perform” rating and boosted their price objective for the stock from $62.00 to $73.00 in a report on Thursday, July 9th. Finally, Robert W. Baird upped their target price on shares of Bio-Techne from $49.00 to $73.00 and gave the stock a “neutral” rating in a research report on Friday, June 26th. Three research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $68.08.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.